RespireRx Pharmaceuticals Inc. (RSPI)
USD 0.0
(15.0%)
USD 0.0
(15.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -1.57 Million USD | 38.29% |
| 2021 | -2.55 Million USD | 22.8% |
| 2020 | -3.31 Million USD | -90.91% |
| 2019 | -1.73 Million USD | 20.22% |
| 2018 | -2.17 Million USD | 48.76% |
| 2017 | -4.24 Million USD | 49.86% |
| 2016 | -8.47 Million USD | -61.69% |
| 2015 | -5.23 Million USD | -20.35% |
| 2014 | -4.35 Million USD | -282.6% |
| 2013 | -1.13 Million USD | 84.48% |
| 2012 | -7.33 Million USD | -224.16% |
| 2011 | -2.26 Million USD | -203.66% |
| 2010 | 2.18 Million USD | 126.18% |
| 2009 | -8.33 Million USD | 44.58% |
| 2008 | -15.03 Million USD | -10.2% |
| 2007 | -13.64 Million USD | 18.28% |
| 2006 | -16.7 Million USD | -37.34% |
| 2005 | -12.16 Million USD | 99.52% |
| 2004 | -2.54 Billion USD | -213457.77% |
| 2003 | -1.18 Million USD | -12.76% |
| 2002 | -1.05 Million USD | 56.02% |
| 2001 | -2.39 Million USD | -1082.7% |
| 2000 | -202.77 Thousand USD | 87.56% |
| 1999 | -1.62 Million USD | 70.16% |
| 1998 | -5.46 Million USD | -7.4% |
| 1997 | -5.08 Million USD | -17.69% |
| 1996 | -4.32 Million USD | 36.45% |
| 1995 | -6.8 Million USD | -44.68% |
| 1994 | -4.7 Million USD | -487.5% |
| 1993 | -800 Thousand USD | 66.67% |
| 1992 | -2.4 Million USD | 7.69% |
| 1991 | -2.6 Million USD | -18.18% |
| 1990 | -2.2 Million USD | -80.33% |
| 1989 | -1.22 Million USD | -258.82% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -390.37 Thousand USD | -76.67% |
| 2023 Q3 | -332.5 Thousand USD | 28.62% |
| 2023 Q2 | -465.85 Thousand USD | -19.34% |
| 2022 Q3 | -388.96 Thousand USD | -10.35% |
| 2022 Q2 | -352.47 Thousand USD | 41.3% |
| 2022 FY | -1.57 Million USD | 38.29% |
| 2022 Q1 | -600.51 Thousand USD | -16.9% |
| 2022 Q4 | -220.96 Thousand USD | 43.19% |
| 2021 Q3 | -581.3 Thousand USD | 12.45% |
| 2021 Q4 | -513.68 Thousand USD | 11.63% |
| 2021 FY | -2.55 Million USD | 22.8% |
| 2021 Q1 | -800.14 Thousand USD | 7.57% |
| 2021 Q2 | -663.99 Thousand USD | 17.01% |
| 2020 Q2 | -616.91 Thousand USD | -18.51% |
| 2020 FY | -3.31 Million USD | -90.91% |
| 2020 Q3 | -1.31 Million USD | -112.67% |
| 2020 Q4 | -865.67 Thousand USD | 34.02% |
| 2020 Q1 | -520.57 Thousand USD | -25.8% |
| 2019 Q4 | -413.79 Thousand USD | 3.87% |
| 2019 Q1 | -473.86 Thousand USD | 18.29% |
| 2019 FY | -1.73 Million USD | 20.22% |
| 2019 Q2 | -418.39 Thousand USD | 11.71% |
| 2019 Q3 | -430.45 Thousand USD | -2.88% |
| 2018 Q4 | -579.92 Thousand USD | -15.16% |
| 2018 Q2 | -586.82 Thousand USD | -15.93% |
| 2018 FY | -2.17 Million USD | 48.76% |
| 2018 Q3 | -503.59 Thousand USD | 14.18% |
| 2018 Q1 | -506.17 Thousand USD | 26.0% |
| 2017 FY | -4.24 Million USD | 49.86% |
| 2017 Q2 | -1.54 Million USD | -9.07% |
| 2017 Q1 | -1.42 Million USD | 2.43% |
| 2017 Q3 | -593.14 Thousand USD | 61.72% |
| 2017 Q4 | -684.06 Thousand USD | -15.33% |
| 2016 FY | -8.47 Million USD | -61.69% |
| 2016 Q2 | -2.34 Million USD | 2.78% |
| 2016 Q3 | -2.24 Million USD | 4.26% |
| 2016 Q1 | -2.41 Million USD | -54.84% |
| 2016 Q4 | -1.45 Million USD | 35.27% |
| 2015 Q4 | -1.56 Million USD | 22.82% |
| 2015 Q2 | -1.06 Million USD | -127.38% |
| 2015 Q1 | -466.33 Thousand USD | 32.31% |
| 2015 FY | -5.23 Million USD | -20.35% |
| 2015 Q3 | -2.02 Million USD | -90.71% |
| 2014 FY | -4.35 Million USD | -282.6% |
| 2014 Q2 | -287.68 Thousand USD | 88.07% |
| 2014 Q1 | -2.41 Million USD | -3981.55% |
| 2014 Q4 | -688.9 Thousand USD | 28.59% |
| 2014 Q3 | -964.74 Thousand USD | -235.34% |
| 2013 Q3 | -58.34 Thousand USD | 67.08% |
| 2013 Q1 | -843.21 Thousand USD | 77.57% |
| 2013 FY | -1.13 Million USD | 84.48% |
| 2013 Q4 | -59.1 Thousand USD | -1.29% |
| 2013 Q2 | -177.23 Thousand USD | 78.98% |
| 2012 Q1 | -934.35 Thousand USD | -212.11% |
| 2012 Q2 | -972 Thousand USD | -4.03% |
| 2012 Q3 | -1.66 Million USD | -71.41% |
| 2012 FY | -7.33 Million USD | -224.16% |
| 2012 Q4 | -3.75 Million USD | -125.64% |
| 2011 Q2 | -363.9 Thousand USD | 76.66% |
| 2011 FY | -2.26 Million USD | -203.66% |
| 2011 Q4 | 833.4 Thousand USD | 171.09% |
| 2011 Q3 | -1.17 Million USD | -222.14% |
| 2011 Q1 | -1.55 Million USD | -58.08% |
| 2010 Q1 | 5.66 Million USD | 484.49% |
| 2010 Q2 | -1.96 Million USD | -134.74% |
| 2010 Q3 | -530.81 Thousand USD | 73.05% |
| 2010 FY | 2.18 Million USD | 126.18% |
| 2010 Q4 | -986.18 Thousand USD | -85.79% |
| 2009 FY | -8.33 Million USD | 44.58% |
| 2009 Q1 | -3.18 Million USD | -0.34% |
| 2009 Q2 | -1.94 Million USD | 38.79% |
| 2009 Q3 | -1.72 Million USD | 11.29% |
| 2009 Q4 | -1.47 Million USD | 14.72% |
| 2008 FY | -15.03 Million USD | -10.2% |
| 2008 Q4 | -3.17 Million USD | 1.8% |
| 2008 Q3 | -3.23 Million USD | 20.74% |
| 2008 Q2 | -4.07 Million USD | 10.6% |
| 2008 Q1 | -4.55 Million USD | -29.36% |
| 2007 Q3 | -3.12 Million USD | -5.08% |
| 2007 Q2 | -2.97 Million USD | 26.19% |
| 2007 Q1 | -4.02 Million USD | -11.92% |
| 2007 FY | -13.64 Million USD | 18.28% |
| 2007 Q4 | -3.52 Million USD | -12.86% |
| 2006 Q1 | -4.7 Million USD | -20.77% |
| 2006 Q4 | -3.59 Million USD | 5.42% |
| 2006 Q3 | -3.8 Million USD | 17.09% |
| 2006 FY | -16.7 Million USD | -37.34% |
| 2006 Q2 | -4.58 Million USD | 2.58% |
| 2005 FY | -12.16 Million USD | 99.52% |
| 2005 Q2 | -2.68 Million USD | 1.35% |
| 2005 Q1 | -2.72 Million USD | 99.89% |
| 2005 Q4 | -3.9 Million USD | -44.87% |
| 2005 Q3 | -2.69 Million USD | -0.12% |
| 2004 Q4 | -2.53 Billion USD | -160329.77% |
| 2004 Q3 | -1.58 Million USD | -11.47% |
| 2004 Q2 | -1.41 Million USD | -76.92% |
| 2004 Q1 | -801.57 Thousand USD | -606.19% |
| 2004 FY | -2.54 Billion USD | -213457.77% |
| 2003 FY | -1.18 Million USD | -12.76% |
| 2003 Q3 | -478.64 Thousand USD | -457.11% |
| 2003 Q2 | -85.91 Thousand USD | 39.44% |
| 2003 Q1 | -141.86 Thousand USD | 49.26% |
| 2003 Q4 | 158.35 Thousand USD | 133.08% |
| 2002 FY | -1.05 Million USD | 56.02% |
| 2002 Q4 | -279.56 Thousand USD | 59.01% |
| 2002 Q3 | -682.04 Thousand USD | -73.84% |
| 2002 Q2 | -392.34 Thousand USD | 53.83% |
| 2002 Q1 | -849.74 Thousand USD | 12.77% |
| 2001 Q1 | -324.71 Thousand USD | 28.06% |
| 2001 Q2 | -264.31 Thousand USD | 18.6% |
| 2001 Q3 | 1.16 Million USD | 539.4% |
| 2001 Q4 | -974.1 Thousand USD | -183.87% |
| 2001 FY | -2.39 Million USD | -1082.7% |
| 2000 Q3 | -1.35 Million USD | -218.27% |
| 2000 FY | -202.77 Thousand USD | 87.56% |
| 2000 Q1 | -652.33 Thousand USD | -57.63% |
| 2000 Q2 | 1.14 Million USD | 275.99% |
| 2000 Q4 | -451.39 Thousand USD | 66.75% |
| 1999 Q2 | -470 Thousand USD | -147.96% |
| 1999 Q4 | -413.85 Thousand USD | -45.4% |
| 1999 Q3 | -284.62 Thousand USD | 39.44% |
| 1999 FY | -1.62 Million USD | 70.16% |
| 1999 Q1 | 980 Thousand USD | 154.44% |
| 1998 Q4 | -1.8 Million USD | -50.0% |
| 1998 Q1 | -1.7 Million USD | -21.43% |
| 1998 Q2 | -1.15 Million USD | 31.88% |
| 1998 Q3 | -1.2 Million USD | -3.63% |
| 1998 FY | -5.46 Million USD | -7.4% |
| 1997 Q4 | -1.4 Million USD | 46.15% |
| 1997 Q3 | -2.6 Million USD | -111.39% |
| 1997 Q2 | -1.22 Million USD | -2.5% |
| 1997 FY | -5.08 Million USD | -17.69% |
| 1997 Q1 | -1.2 Million USD | 14.29% |
| 1996 Q1 | -1.1 Million USD | 8.33% |
| 1996 Q4 | -1.4 Million USD | -16.67% |
| 1996 Q3 | -1.2 Million USD | -25.23% |
| 1996 Q2 | -958.24 Thousand USD | 12.89% |
| 1996 FY | -4.32 Million USD | 36.45% |
| 1995 FY | -6.8 Million USD | -44.68% |
| 1995 Q2 | -2.8 Million USD | -133.33% |
| 1995 Q3 | -1 Million USD | 64.29% |
| 1995 Q4 | -1.2 Million USD | -20.0% |
| 1995 Q1 | -1.2 Million USD | 62.5% |
| 1994 Q3 | -1.4 Million USD | 0.0% |
| 1994 FY | -4.7 Million USD | -487.5% |
| 1994 Q4 | -3.2 Million USD | -128.57% |
| 1994 Q2 | -1.4 Million USD | 2.78% |
| 1994 Q1 | -1.44 Million USD | -38.46% |
| 1993 FY | -800 Thousand USD | 66.67% |
| 1993 Q1 | -240 Thousand USD | -250.0% |
| 1993 Q2 | -300 Thousand USD | -25.0% |
| 1993 Q3 | -940 Thousand USD | -213.33% |
| 1993 Q4 | -1.04 Million USD | -10.64% |
| 1992 FY | -2.4 Million USD | 7.69% |
| 1992 Q1 | -430 Thousand USD | 48.19% |
| 1992 Q2 | -540 Thousand USD | -25.58% |
| 1992 Q3 | -440 Thousand USD | 18.52% |
| 1992 Q4 | 160 Thousand USD | 136.36% |
| 1991 FY | -2.6 Million USD | -18.18% |
| 1991 Q1 | -720 Thousand USD | -14.29% |
| 1991 Q4 | -830 Thousand USD | 0.0% |
| 1991 Q3 | -830 Thousand USD | 0.0% |
| 1991 Q2 | -830 Thousand USD | -15.28% |
| 1990 Q2 | -610 Thousand USD | 1.61% |
| 1990 FY | -2.2 Million USD | -80.33% |
| 1990 Q3 | -530 Thousand USD | 13.11% |
| 1990 Q4 | -630 Thousand USD | -18.87% |
| 1990 Q1 | -620 Thousand USD | -16.98% |
| 1989 Q4 | -530 Thousand USD | -1.92% |
| 1989 Q2 | -320 Thousand USD | -420.0% |
| 1989 Q3 | -520 Thousand USD | -62.5% |
| 1989 Q1 | 100 Thousand USD | 0.0% |
| 1989 FY | -1.22 Million USD | -258.82% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -18.266% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 68.691% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 91.151% |
| Nascent Biotech, Inc. | -2.22 Million USD | 29.173% |
| Rebus Holdings, Inc. | -664 Thousand USD | -137.855% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.93% |
| Qrons Inc. | -643.67 Thousand USD | -145.365% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -305.41% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 97.155% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -280.129% |
| Skye Bioscience, Inc. | -13.67 Million USD | 88.448% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 97.8% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 132.135% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -503.438% |
| SQZ Biotechnologies Company | -75.82 Million USD | 97.917% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 44.594% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -2.819% |
| Mesoblast Limited | -84.14 Million USD | 98.123% |
| Marizyme, Inc. | -34.08 Million USD | 95.367% |
| Genus plc | 6.4 Million USD | 124.677% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 116.211% |
| Pharming Group N.V. | -4.87 Million USD | 67.633% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 20.495% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -69.571% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 81.086% |
| ContraFect Corporation | -56.88 Million USD | 97.224% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 65.325% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -12.651% |
| IMV Inc. | -38.67 Million USD | 95.916% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 42.586% |
| MultiCell Technologies, Inc. | -722.81 USD | -218402.096% |
| ONE Bio Corp. | 13.68 Million USD | 111.544% |
| Accustem Sciences Inc. | -3.74 Million USD | 57.844% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 97.323% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -226.947% |
| Q BioMed Inc. | -3.44 Million USD | 54.163% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 144.615% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 39.892% |
| Biomind Labs Inc. | -1 Million USD | -56.433% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 97.127% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 45.563% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 76.243% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 15.287% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -5172.953% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 90.048% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 18.279% |
| GB Sciences, Inc. | -1.42 Million USD | -11.182% |
| Alpha Cognition Inc. | -9.7 Million USD | 83.727% |
| HST Global, Inc. | -140.9 Thousand USD | -1020.849% |
| CSL Limited | 3.7 Billion USD | 100.043% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -40.399% |
| Halberd Corporation | -75.05 Thousand USD | -2004.404% |
| Enzolytics Inc. | -2.14 Million USD | 26.501% |
| Agentix Corp. | -1.37 Million USD | -15.134% |
| Resverlogix Corp. | -12.74 Million USD | 87.612% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 50.151% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.628% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -51.279% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 45.902% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 53.616% |
| AVAX Technologies, Inc. | 6.69 Million USD | 123.598% |
| Zenith Capital Corp. | -8.94 Million USD | 82.34% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.62% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -8965.811% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 35.676% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -820.855% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 21.22% |
| Kadimastem Ltd | -3.04 Million USD | 48.052% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -60.495% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -25.745% |
| BioStem Technologies, Inc. | -7.77 Million USD | 79.697% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -770.24% |
| LadRx Corporation | -3.82 Million USD | 58.695% |
| Cell Source, Inc. | -4.32 Million USD | 63.486% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -129.908% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -129.908% |
| NovAccess Global Inc. | -2.46 Million USD | 35.975% |
| Affymax, Inc. | -15.04 Million USD | 89.503% |
| Itoco Inc. | -919.14 Thousand USD | -71.83% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 62.737% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -41.14% |
| Mobile Lads Corp. | -554.55 Thousand USD | -184.799% |
| CytoDyn Inc. | -18.05 Million USD | 91.254% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -6174.752% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -617.634% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -179.669% |
| SYBLEU INC | -149.18 Thousand USD | -958.691% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 13.046% |
| International Stem Cell Corporation | -663 Thousand USD | -138.213% |
| Bioxytran, Inc. | -3.82 Million USD | 58.657% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2900.294% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -7664.774% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 95.645% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 2.388% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -114.634% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 49.233% |
| Neutra Corp. | -229.48 Thousand USD | -588.214% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 90.995% |
| PureTech Health plc | -146.19 Million USD | 98.92% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 92.651% |
| IXICO plc | -1.43 Million USD | -9.906% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 83.359% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.703% |
| CSL Limited | 3.81 Billion USD | 100.041% |
| Cellectis S.A. | -108.85 Million USD | 98.549% |